Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma

46Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. Methods: PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI were performed to detect drug levels in the brain. EGFR levels and compensatory pathways were studied using quantitative flow cytometry, Western blots, RNAseq, FISH, and phosphoproteomics. Results: Systemic delivery of Depatux-M was highly effective in nine of 10 EGFR-amplified heterotopic PDXs with survival extending beyond one year in eight PDXs. Acquired resistance in two PDXs (GBM12 and GBM46) was driven by suppression of EGFR expression or emergence of a novel short-variant of EGFR lacking the epitope for the Depatux-M antibody. In contrast to the profound benefit observed in heterotopic tumors, only two of seven intrinsically sensitive PDXs were responsive to Depatux-M as intracranial tumors. Poor efficacy in orthotopic PDXs was associated with limited and heterogeneous distribution of Depatux-M into tumor tissues, and artificial disruption of the BBB or bypass of the BBB by direct intracranial injection of Depatux-M into orthotopic tumors markedly enhanced the efficacy of drug treatment. Conclusions: Despite profound intrinsic sensitivity to Depatux-M, limited drug delivery into brain tumor may have been a key contributor to lack of efficacy in recently failed clinical trials.

References Powered by Scopus

Trastuzumab emtansine for residual invasive HER2-positive breast cancer

1887Citations
N/AReaders
Get full text

Monoclonal antibodies: Versatile platforms for cancer immunotherapy

1011Citations
N/AReaders
Get full text

Targeting the EGFR signaling pathway in cancer therapy

749Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Glioma targeted therapy: insight into future of molecular approaches

426Citations
N/AReaders
Get full text

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

67Citations
N/AReaders
Get full text

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

46Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Marin, B. M., Porath, K. A., Jain, S., Kim, M., Conage-Pough, J. E., Oh, J. H., … Sarkaria, J. N. (2021). Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology, 23(12), 2042–2053. https://doi.org/10.1093/neuonc/noab133

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

83%

Researcher 2

17%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 4

33%

Medicine and Dentistry 4

33%

Biochemistry, Genetics and Molecular Bi... 3

25%

Chemical Engineering 1

8%

Save time finding and organizing research with Mendeley

Sign up for free